Literature DB >> 20488655

Uterine arteriovenous fistula necessitating hysterectomy after two unsuccessful embolizations in an 18-year-old patient.

Na Guo1, Hui Liu, Zhilan Peng.   

Abstract

Uterine arteriovenous fistula is a rare, but potentially life-threatening condition that should be suspected in women of reproductive age with an unexplained vaginal bleeding. Uterine artery embolization, in contrast, is a safe and effective treatment for uterine arteriovenous fistula because it preserves the normal function of the uterus and the ovaries. The advantages of avoiding hysterectomy are clear, especially for young patients who want to preserve their reproductive function. Embolization failure is rare. When a uterine arteriovenous fistula reappears, it is necessary to perform subsequent embolization, especially in young patients, to treat the fistula effectively. The patient in this study had two unsuccessful embolizations, resulting in massive vaginal hemorrhage. This endangered the patient's life, and thus, a hysterectomy was performed, although the patient was infertile. Cases of unsuccessful embolizations, such as this, are unusual. Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20488655     DOI: 10.1016/j.avsg.2010.02.041

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  2 in total

1.  Management of bleeding uterine arteriovenous malformation with bilateral uterine artery embolization.

Authors:  Taehwan Kim; Ji Hoon Shin; Jinoo Kim; Hyun-Ki Yoon; Gi-Young Ko; Dong-Il Gwon; Heechul Yang; Kyu-Bo Sung
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

2.  Accuracy of flow-void diameters on MR images in diagnosing uterine arteriovenous malformations in patients with pregnancy-related diseases.

Authors:  Hui-Zhu Chen; Fu-Min Zhao; Ling-Jun Liu; Xiao-Hui Dai; Xue-Sheng Li; Gang Ning; Ying-Kun Guo
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.